1. Complex “Cross Talk” Involving Nitric Oxide Metabolites: Who’s Listening?

   • David P. Hajjar
   • Ruba S. Deeb
   • Rita K. Upmacis

   Invited Commentary Pages: 347 - 348

2. Web alert

   • Robert Chilton

   Announcement Pages: 349 - 349

3. Clinical Trials Report

   • Peter P. Toth

   OriginalPaper Pages: 353 - 355

4. Fibrate therapy in patients with metabolic syndrome and diabetes mellitus

   • Thomas Dayspring
   • Gregory Pokrywka

   OriginalPaper Pages: 356 - 364

5. Apolipoprotein A-I and risk for cardiovascular diseases

   • Natalie Khuseyinova
   • Wolfgang Koenig

   OriginalPaper Pages: 365 - 373

6. Lipoprotein-associated phospholipase A₂: Pathogenic mechanisms and clinical utility for predicting cardiovascular events

   • Vijay Nambi
   • Christie M. Ballantyne

   OriginalPaper Pages: 374 - 381

7. Are lower levels of low-density lipoprotein cholesterol beneficial? A review of recent data

   • Anders G. Olsson

   ReviewPaper Pages: 382 - 389

8. Statins and the primary prevention of cardiovascular events

   • Michael Clearfield

   OriginalPaper Pages: 390 - 396

9. Impact of thiazolidenediones on serum lipoprotein levels

   • Ronald B. Goldberg

   OriginalPaper Pages: 397 - 404

10. High-density lipoprotein: Is it always atheroprotective?

    • Benjamin J. Ansell
    • Gregg C. Fonarow
    • Alan M. Fogelman

    OriginalPaper Pages: 405 - 411

11. Clinical insights into the diagnosis and management of atherosclerotic renal artery disease

    • Michael J. Bloch
    • Jan Basile

    OriginalPaper Pages: 412 - 420

12. C-reactive protein and cardiovascular disease: Weighing the evidence

    • Gordon D. O. Lowe
    • Mark B. Pepys

    OriginalPaper Pages: 421 - 428

13. The CARDS trial: Diabetic patients dealt a winning hand

    • Annemarie Armani
    • Peter P. Toth

    OriginalPaper Pages: 429 - 432

14. Hypoadiponectinemia: A common basis for diseases associated with overnutrition

    • Tohru Funahashi
    • Yuji Matsuzawa

    OriginalPaper Pages: 433 - 438